Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of long-term oral Vimpat (SPM 927) in patients with partial seizures
2014-004398-18Phase 3
- Sponsor
- UCB
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lacosamide in epilepsy and Focal Onset Epilepsy, sponsored by UCB. Primary endpoint: Number of subjects reporting at least 1 treatment-emergent adverse event (TEAE) during the treatment period.
02
Drugs
lacosamide
03
Conditions
epilepsyFocal Onset Epilepsy
Beyond the preview
Go deeper on 2014-004398-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004398-18.